All In Biotech

NDA 022426 · Takeda Pharms USA

Oseni

Alogliptin Benzoate, Pioglitazone Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Jun 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Jan 25, 2013

Approved uses

3

Original approval plus efficacy supplements

Registered trials

6

1 Phase 3, 0 recruiting

FAERS reports

249

67 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CONGESTIVE HEART FAILURE Thiazolidinediones, including pioglitazone, which is a component of alogliptin and pioglitazone tablets, cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1) ] . After initiation of alogliptin and pioglitazone tablets and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea and/or edema). If congestive heart failure develops while taking alogliptin and pioglitazone tablets, consider discontinuation of alogliptin and pioglitazone tablets or dosage reduction of pioglitazone in alogliptin and pioglitazone tablets [see Warnings and Precautions (5.1) ] . Alogliptin and pioglitazone tablets are not recommended in patients with symptomatic heart failure [see Warnings and Precautions (5.1) ] . Initiation of alogliptin and pioglitazone...

What it is approved for

From the label in effect Jul 28, 2025.

Alogliptin and pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Alogliptin and pioglitazone tablets are a combination of alogliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone, a thiazolidinedione agonist of peroxisome proliferator receptor gamma, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Alogliptin and pioglitazone tablets are not recommended for use in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Alogliptin and pioglitazone tablets are not recommended for use in patients with type 1 diabetes mellitus.

Mechanism: Alogliptin and pioglitazone tablets combine two antihyperglycemic agents: alogliptin and pioglitazone. Alogliptin Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the dipeptidyl peptidase-4 (DPP-4) enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 12, 2016 Supplement 6 · Efficacy Letter
  • Apr 5, 2016 Supplement 3 · Efficacy LabelLetter
  • Jan 25, 2013 Original approval · Type 4 - New Combination OtherLabelReview
6 products under this application
  • OSENI · ALOGLIPTIN BENZOATE EQ 12.5MG BASE; PIOGLITAZONE HYDROCHLORIDE EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • OSENI · ALOGLIPTIN BENZOATE EQ 12.5MG BASE; PIOGLITAZONE HYDROCHLORIDE EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • OSENI · ALOGLIPTIN BENZOATE EQ 25MG BASE; PIOGLITAZONE HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Prescription
  • OSENI · ALOGLIPTIN BENZOATE EQ 12.5MG BASE; PIOGLITAZONE HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Prescription
  • OSENI · ALOGLIPTIN BENZOATE EQ 25MG BASE; PIOGLITAZONE HYDROCHLORIDE EQ 45MG BASE · TABLET, ORAL · Prescription
  • OSENI · ALOGLIPTIN BENZOATE EQ 25MG BASE; PIOGLITAZONE HYDROCHLORIDE EQ 15MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Alogliptin Benzoate" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • weight increased21
  • drug ineffective11
  • fatigue11
  • rash11
  • blood glucose increased10
  • pancreatitis10
  • headache9
  • vision blurred9
  • arthralgia8
  • myalgia8
  • nausea8
  • abdominal pain upper7

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20133
201463
2015103
201632
201713
20189
20197
20206
20215
20221
20242
20254
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Oseni (Alogliptin Benz/Pioglitazone)

2024 spending

$49K

Beneficiaries

41

64 claims

Per beneficiary

$1,188

$12.79 per unit

View as table
YearSpending
2020$710,649
2021$526,636
2022$394,915
2023$256,634
2024$48,722

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.